OBJECTIVES: To investigate cost-effectiveness and incremental cost-effectiveness ratio for basic and immunotropic therapy. METHODS: In cost-effectiveness analysis the cost consist of expenditures for in-patient, out-patient and emergency care, pharmacotherapy and indirect expenditures for temporary invalidity of parents and non-payment taxes. During one year prospective randomize simultaneous investigation was conducted in 150 children with middle severe asthma. The patients of the first group (50 children) were treated by sodium cromoglycate as basic therapy, the second group (50 children) - sodium nedocromil, the third group (50 children)- combination of sodium nedocromil and broncho-munal. Cost-effectiveness criterion was included the cost of one asymptomatic day per year with determination clinico-immunological indices. RESULTS: Investigation was revealed that clinical effectiveness basic and immunotropic therapy was difference. The most prolonged (341,4±1,96 days) asymptomatic period was defined in patients of the third group, the cost of one asymptomatic day was the lowest (8,97±0,21 rubles) per year. Comparing with the first group in the second one expenditures was increased insignificantly (+6,73 rubles) and effectiveness was increased considerably (+24,3 days), incremental cost-effectiveness ratio was low (?C/?E = 0,277). Inverse dynamics of total expenditures (-1990,17 rubles) and increasing of treatment effectiveness (+8,6 days, p<0,01) was defined including broncho-munal therapy, incremental cost-effectiveness ratio was -231,42. COCLUSION: Increasing treatment effectiveness and decreasing expenditures was determined including broncho-munal in complex therapy. Correlation between cost and treatment effectiveness was rational in complex therapy of child's asthma with broncho-munal and sodium nedocromil.